Details for Patent: 11,597,692

Which drugs does patent 11,597,692 protect, and when does it expire?

Patent 11,597,692 protects VTAMA and is included in one NDA.

This patent has twenty-seven patent family members in fourteen countries.

Summary for Patent: 11,597,692

Title:	Process for preparing tapinarof
Abstract:	The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2-isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same.
Inventor(s):	Ian Paul Andrews, Nicholas CALANDRA, Tyler Andrew DAVIS, Ravinder Reddy Sudini
Assignee:	Dermavant Sciences GmbH , GlaxoSmithKline Intellectual Property Development Ltd
Application Number:	US17/174,566
Patent Claim Types: see list of patent claims	Composition; Compound; Process;

Drugs Protected by US Patent 11,597,692

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes			Y	Y

International Family Members for US Patent 11,597,692

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018365241
Australia	2023274224
Brazil	112020009158